NYSE:TFX - Teleflex Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Teleflex Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $329.66 -7.44 (-2.21 %) (As of 02/28/2020 01:51 PM ET) Add Compare Today's Range$315.73Now: $329.66▼$333.1650-Day Range$337.10MA: $377.72▼$395.1452-Week Range$271.56Now: $329.66▼$398.65Volume13,367 shsAverage Volume197,922 shsMarket Capitalization$15.28 billionP/E Ratio33.71Dividend Yield0.39%Beta0.94 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:TFX Previous Symbol CUSIP87936910 CIK96943 Webhttp://www.teleflex.com/ Phone610-225-6800Debt Debt-to-Equity Ratio0.66 Current Ratio2.32 Quick Ratio1.47Price-To-Earnings Trailing P/E Ratio33.71 Forward P/E Ratio26.08 P/E Growth1.91 Sales & Book Value Annual Sales$2.60 billion Price / Sales5.89 Cash Flow$15.33 per share Price / Cash Flow21.50 Book Value$64.26 per share Price / Book5.13Profitability EPS (Most Recent Fiscal Year)$11.15 Net Income$461.47 million Net Margins17.78% Return on Equity18.97% Return on Assets8.35%Miscellaneous Employees15,200 Outstanding Shares46,360,000Market Cap$15.28 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive TFX News and Ratings via Email Sign-up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter. TFX Rates by TradingView Teleflex (NYSE:TFX) Frequently Asked Questions What is Teleflex's stock symbol? Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX." How often does Teleflex pay dividends? What is the dividend yield for Teleflex? Teleflex announced a quarterly dividend on Thursday, February 20th. Investors of record on Monday, March 2nd will be paid a dividend of $0.34 per share on Monday, March 16th. This represents a $1.36 annualized dividend and a yield of 0.41%. The ex-dividend date is Friday, February 28th. View Teleflex's Dividend History. How were Teleflex's earnings last quarter? Teleflex Incorporated (NYSE:TFX) released its quarterly earnings data on Thursday, February, 20th. The medical technology company reported $3.28 EPS for the quarter, beating the Zacks' consensus estimate of $3.22 by $0.06. The medical technology company had revenue of $681 million for the quarter, compared to analyst estimates of $679.01 million. Teleflex had a return on equity of 18.97% and a net margin of 17.78%. The business's quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.77 EPS. View Teleflex's Earnings History. When is Teleflex's next earnings date? Teleflex is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Teleflex. What guidance has Teleflex issued on next quarter's earnings? Teleflex issued an update on its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $12.50-12.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.68. The company issued revenue guidance of $2.764-2.790 billion, compared to the consensus revenue estimate of $2.78 billion. What price target have analysts set for TFX? 10 brokerages have issued 1 year price objectives for Teleflex's stock. Their forecasts range from $378.00 to $450.00. On average, they anticipate Teleflex's stock price to reach $413.73 in the next year. This suggests a possible upside of 24.4% from the stock's current price. View Analyst Price Targets for Teleflex. What is the consensus analysts' recommendation for Teleflex? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teleflex. What are Wall Street analysts saying about Teleflex stock? Here are some recent quotes from research analysts about Teleflex stock: 1. According to Zacks Investment Research, "Teleflex exited the first quarter of 2019 on a solid note with better-than-expected earnings and revenues figures. The promising performance was driven by strong growth in Interventional Urology, Interventional Access and OEM. Geographically, Asia and Americas both registered strong constant currency revenue growth. We currently look forward to Urolift’s impending limited launch Japan following its Shonn approval. This apart, Teleflex announced a major reimbursement milestone for Urolift of receiving a positive coverage decision from health insurer Humana. Vascular solutions synergy is progressing well. Management also seems to be confident about its recently completed Essential Medical buyout. On the flip side, escalating operating expenses are putting pressure on the bottom line. Tough competition and pricing pressure also weigh on the stock. Overall, in the past three months, shares of Teleflex consistently outperformed its industry." (5/14/2019) 2. Needham & Company LLC analysts commented, "TFX is changing its product categories and segments and we have updated our revenue model to reflect the changes. While we are maintaining our prior total revenue and EPS estimates, we are publishing our estimates for the new product categories and segments. We view RePlas as potential sources of upside to TFX’s 2019 guidance and we reiterate our Strong Buy rating." (3/26/2019) Has Teleflex been receiving favorable news coverage? News coverage about TFX stock has trended very negative recently, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teleflex earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the medical technology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Teleflex. Are investors shorting Teleflex? Teleflex saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 606,200 shares, a decrease of 5.0% from the January 30th total of 638,200 shares. Based on an average trading volume of 207,400 shares, the short-interest ratio is presently 2.9 days. Currently, 1.3% of the shares of the stock are short sold. View Teleflex's Current Options Chain. Who are some of Teleflex's key competitors? Some companies that are related to Teleflex include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD). What other stocks do shareholders of Teleflex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Teleflex investors own include Alibaba Group (BABA), Visa (V), NVIDIA (NVDA), AbbVie (ABBV), Netflix (NFLX), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH), Lam Research (LRCX), ServiceNow (NOW) and ABIOMED (ABMD). Who are Teleflex's key executives? Teleflex's management team includes the folowing people: Mr. Liam J. Kelly, Pres, CEO & Director (Age 52)Mr. Thomas E. Powell, Exec. VP & CFO (Age 57)Mr. James J. Leyden, VP, Gen. Counsel & Sec. (Age 52)Mr. John R. Deren, VP & Chief Accounting OfficerMr. Timothy F. Duffy, Chief Information Officer & VP Who are Teleflex's major shareholders? Teleflex's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.12%), Janus Henderson Group PLC (1.95%), Marshall Wace LLP (1.57%), Geode Capital Management LLC (1.56%), William Blair Investment Management LLC (1.48%) and Goldman Sachs Group Inc. (1.24%). Company insiders that own Teleflex stock include Andrew A Krakauer, Benson Smith, Cameron P Hicks, George Babich Jr, James J Leyden, John C Heinmiller, John Deren, Karen Boylan, Stephen K MD Klasko, Stuart A Randle, Thomas Anthony Kennedy and Thomas E Powell. View Institutional Ownership Trends for Teleflex. Which major investors are selling Teleflex stock? TFX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, Janus Henderson Group PLC, Rice Hall James & Associates LLC, Principal Financial Group Inc., Marshall Wace North America L.P., FIL Ltd and USS Investment Management Ltd. Company insiders that have sold Teleflex company stock in the last year include Benson Smith, Cameron P Hicks, James J Leyden, John Deren, Karen Boylan, Stephen K MD Klasko, Stuart A Randle and Thomas E Powell. View Insider Buying and Selling for Teleflex. Which major investors are buying Teleflex stock? TFX stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Montag & Caldwell LLC, Scout Investments Inc., AMI Asset Management Corp, Lord Abbett & CO. LLC, Victory Capital Management Inc., Kornitzer Capital Management Inc. KS and Victory Capital Management Inc.. Company insiders that have bought Teleflex stock in the last two years include Andrew A Krakauer and John C Heinmiller. View Insider Buying and Selling for Teleflex. How do I buy shares of Teleflex? Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Teleflex's stock price today? One share of TFX stock can currently be purchased for approximately $332.45. How big of a company is Teleflex? Teleflex has a market capitalization of $15.41 billion and generates $2.60 billion in revenue each year. The medical technology company earns $461.47 million in net income (profit) each year or $11.15 on an earnings per share basis. Teleflex employs 15,200 workers across the globe.View Additional Information About Teleflex. What is Teleflex's official website? The official website for Teleflex is http://www.teleflex.com/. How can I contact Teleflex? Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected] MarketBeat Community Rating for Teleflex (NYSE TFX)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 427 (Vote Outperform)Underperform Votes: 544 (Vote Underperform)Total Votes: 971MarketBeat's community ratings are surveys of what our community members think about Teleflex and other stocks. Vote "Outperform" if you believe TFX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TFX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/28/2020 by MarketBeat.com StaffFeatured Article: What is the outlook for the FAANG stocks?
